Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ODN/Pam2 - Pulmotect

Drug Profile

ODN/Pam2 - Pulmotect

Alternative Names: ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042

Latest Information Update: 09 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pulmotect
  • Developer Cancer Prevention & Research Institute of Texas; National Heart, Lung and Blood Institute; Pulmotect; University of Texas M. D. Anderson Cancer Center
  • Class Antisense oligonucleotides; Lipopeptides
  • Mechanism of Action Immunostimulants; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease; COVID 2019 infections
  • Phase I Haematological malignancies
  • Preclinical Lung disorders
  • No development reported Pneumocystis pneumonia

Most Recent Events

  • 04 Jun 2020 Phase-II clinical trials in COVID-2019 infections (Prevention) in USA (Inhalation) (NCT04313023)
  • 13 May 2020 Phase-II clinical trials in COVID-2019 infections (Adjunctive treatment) in USA (Inhalation) (NCT04312997)
  • 11 May 2020 Preclinical trials in COVID-2019 infections (Prevention) in USA (Inhalation) before May
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top